Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 985 of 6351
-
New combo therapy aims to shrink untreatable liver tumors
Disease control OngoingA Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with Y-90 SIRT for intermediate stage HCC
Phase 2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Triple-Drug cocktail aims to boost remission in CLL
Disease control OngoingThis study is testing the effectiveness of the study drug combination of acalabrutinib, umbralisib, and ublituximab in participants with Chronic Lymphocytic leukemia (CLL). The names of the study drugs involved in this study are/is: * Acalabrutinib (CALQUENCE®, ACP-196) * Umbra…
Phase 2 • Sponsor: Jennifer R. Brown, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Double antibody attack shows promise for Hard-to-Treat myeloma
Disease control OngoingThe purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R\[s\]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab i…
Phase 1/2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug cocktail aims to outperform current lung cancer therapy
Disease control CompletedThe purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with pembrolizumab plus pemetrexed and carboplatin/cisplatin …
Phase 2/3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Peppermint and lemon scents put to the test against chemo nausea
Symptom relief CompletedThe investigator wish to provide a blend of two essential oils with comparable antiemetic properties; Peppermint essential oil (Mentha x Piperita) and lemon tree essential oil (Citrus Limon). Dry inhalation of these essential oils is safe, but effectiveness has not been determine…
Phase 2 • Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
Can a structured recovery plan speed healing after sarcoma surgery?
Symptom relief Recruiting nowThe purpose of this study is to demonstrate the efficacy of implementing the enhanced recovery after surgery (ERAS) pathway in a prospective manner to patients undergoing surgical treatment for extremity sarcoma.
Sponsor: Joshua Lawrenz • Aim: Symptom relief
Last updated Aug 23, 2026 00:00 UTC
-
New combo attack: virus and supercharged immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Gene therapy for wet AMD: could this mean fewer eye injections?
Disease control OngoingADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).
Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo shows promise in Tough-to-Treat head and neck cancer
Disease control CompletedThe BURAN study is a randomized, open-label phase III study to assess the treatment effect of once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel alone in patients with refractory, recurrent, or metastatic head and neck squamous cell carcinom…
Phase 3 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Could skipping hormone pills lower blood pressure risks in IVF?
Disease control CancelledRecent sutdies indicate that the existence of corpus lutein in the ovary is a key point to prevent preeclampsia, and patients undergoing FET with hormone replaced cycle have no corpus lutein and the absence of corpus lutein significantly increases the risk of preeclampsia in thes…
Sponsor: Women's Hospital School Of Medicine Zhejiang University • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New hope for stem cell transplant patients with dangerous blood clotting disorder
Disease control CompletedThis study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab in adult and adolescent participants with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). In Stage 1, an open-label, single-arm period, the do…
Phase 3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a new suppository bring remission to ulcerative proctitis?
Disease control CompletedA randomized, multi-center, double-blind, three arm placebo-controlled study in male and non-pregnant, non-lactating female subjects aged 18 years to examine the safety and efficacy of two dosing regimens of hydrocortisone acetate 90 mg suppository administered with the Sephure s…
Phase 3 • Sponsor: Cristcot HCA LLC • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for HIV patients with lung cancer: immunotherapy combo trial opens
Disease control Recruiting nowThis is a phase II trial of durvalumab and tremelimumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection will be eligible. Patients will receive standard platinum-based chemo…
Phase 2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could a Once-a-Day inhaler replace frequent treatments for COPD emergencies?
Disease control CompletedThe purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized Albuterol and Ipratropium.
Phase 4 • Sponsor: University of Tennessee Graduate School of Medicine • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can tracking 5,000 stroke survivors unlock better recovery?
Knowledge-focused OngoingStroke is the second leading cause of death and one of the main contributors to disability. Patients who survive the acute phase of ischemic stroke and those with transient ischemic attack (TIA) are at high risk of subsequent vascular events. Importantly, recurrent strokes are as…
Sponsor: VASCage GmbH • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThe Phase 1 part (Part A) is a dose escalation study of IV visugromab (CTL-002, a monoclonal antibody neutralizing GDF-15) as monotherapy and in combination with an approved checkpoint inhibitor (CPI) in patients with advanced solid tumors. Enrolment into the Ph 1 part is comple…
Phase 1/2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New antibody cocktail takes on tough ovarian cancers
Disease control Recruiting nowThis study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without…
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Experimental drug shows promise for rare genetic syndrome in toddlers
Disease control OngoingThis study will investigate the effect of treatment with tiratricol (also called Triac) in young boys (≤30 months) with MCT8 deficiency (also called the Allan-Herndon-Dudley syndrome (AHDS)). The hypothesis tested is that treatment with tiratricol will have a beneficial effect on…
Phase 2 • Sponsor: Rare Thyroid Therapeutics International AB • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Blood test may forecast kidney transplant rejection before it happens
Diagnosis Recruiting nowAcute rejection after kidney transplantation should ideally be diagnosed prior to immunologic injury in a non-invasive fashion in order to improve long-term graft function. Donor-derived cell-free DNA (ddcfDNA) is a promising method to do so as it is elevated prior to acute rejec…
Sponsor: Loma Linda University • Aim: Diagnosis
Last updated Aug 23, 2026 00:00 UTC
-
New ultrasound technique may predict chemo success early in breast cancer
Diagnosis OngoingThis phase II/III trial studies if contrast-enhanced ultrasounds using a contrast dye, perflutren lipid microspheres (Definity), can predict the response to chemotherapy by estimating the pressure in the cancer in patients with breast cancer that has spread to nearby tissues and …
Phase 2/3 • Sponsor: Kibo Nam • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC